On November 30, 2022 Promontory Therapeutics Inc., a clinical stage pharmaceutical company advancing small molecule immunotherapies in oncology, will present clinical data on lead therapeutic candidate, PT-112, in combination with avelumab, and its immunogenic cell death inducing effects in patients with advanced non-small cell lung cancer as a poster presentation at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2022 in Geneva, Switzerland, on Dec. 7-9 (Press release, Promontory Therapeutics, NOV 30, 2022, View Source [SID1234624612]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Session Details
Title: A phase 2a study of the novel immunogenic cell death (ICD) inducer PT-112 plus avelumab ("PAVE") in advanced non-small cell lung cancer (NSCLC) patients (pts)
Presentation Number: 125P
Session location: Foyer ABC, Palexpo Exhibition Centre
Session time: Thursday, December 8, 2022, 12:30 p.m. to 1:15 p.m. CET
Speaker/Lead Author: Martina Imbimbo, MD, Lausanne University Hospital, Switzerland

Abstracts will be published online on the ESMO (Free ESMO Whitepaper) website at 12:05 a.m. CET on Thursday, Dec. 1, 2022. Abstracts will also be published online in the ESMO (Free ESMO Whitepaper)-IO Congress 2022 Abstract Book, a supplement to the official ESMO (Free ESMO Whitepaper) journal, Immuno-Oncology and Technology (IOTECH).

For more information about PT-112 and Promontory Therapeutics’ clinical pipeline visit www.PromontoryTx.com.

About PT-112

PT-112 is the first small-molecule conjugate of pyrophosphate in oncology, and possesses a unique pleiotropic mechanism of action that promotes immunogenic cell death (ICD), through the release of damage associated molecular patterns (DAMPs) that bind to dendritic cells and lead to downstream immune effector cell recruitment in the tumor microenvironment. PT-112 represents a highly potent inducer of this immunological form of cancer cell death. Further, PT-112 harbors a property known as osteotropism, or the propensity of the drug to reach its highest concentrations in certain areas of the bone, making it a candidate for treatment of patients with cancers that originate in, or metastasize to, the bone. The first in-human study of PT-112 demonstrated an attractive safety profile and evidence of long-lasting responses among heavily pre-treated patients and won "Best Poster" within the Developmental Therapeutics category at the ESMO (Free ESMO Whitepaper) 2018 Annual Congress. The combination Phase 1b dose escalation study of PT-112 with PD-L1 checkpoint inhibitor avelumab in solid tumors was reported in an oral presentation at the ESMO (Free ESMO Whitepaper) 2020 Virtual Congress and the Phase 2a dose confirmation cohort in non-small cell lung cancer (NSCLC) patients will be reported at ESMO (Free ESMO Whitepaper) IO 2022. The Phase 1 study in patients with relapsed or refractory multiple myeloma presented at ASH (Free ASH Whitepaper) is the third completed Phase 1 study of PT-112. Monotherapy Phase 2 development is ongoing in mCRPC, and now includes the Phase 2 proof of concept study in thymic epithelial tumors under the company’s formal collaboration with the NCI.

On November, 2022 Onxeo S.A. (Euronext Growth Paris: ALONX), hereafter "Onxeo" or the "Company", a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), reported the expansion of its pipeline of drug candidates with OX425, the optimized new compound of OX400 series sourced from its proprietary PlatON platform (Press release, Onxeo, NOV 30, 2022, View Source [SID1234624611]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

OX425 is a new-generation decoy oligonucleotide (ODN) with a well differentiated mechanism of action from PARP inhibitors as it drives PARP-1 hyperactivation and leads to exhaustion of the DNA damage response, ultimately killing cancer cells. In addition, it also leads to activation of the STING pathway. In preclinical proof-of-concept studies performed to date, OX425 demonstrated high antitumor activity while sparing healthy cells. It also showed the ability to mediate multiple immunostimulatory effects, standing out as promising option for potential combination with immunotherapy, especially in tumors that are not attackable by the immune system ("cold" tumors).

Like the other drug candidates sourced from platON, such as AsiDNA, OX425’s benefits from decoy agonist mechanism of action and does not induce tumor resistance to treatment. This profile represents a clear differentiation from other targeted therapies such as PARP inhibitors. Moreover, OX425 shows no activity on healthy cells, which should yield a favorable safety profile in the clinical setting.

Based on these promising results, Onxeo will complete the preclinical development with the objective to file an Investigational New Drug (IND) with the FDA in mid of 2023.

Dr. Shefali Agarwal, President and CEO of Onxeo, stated: "With the selection of OX425, we demonstrate once again our ability to source new drug candidates with distinctive properties based on the unique decoy mechanism of action which is the technological engine of our PlatON platform. OX425 showed robust antitumor activity during our preclinical studies in multiple solid tumor models from different indications. OX425 is thus positioned as an innovative monotherapy and an ideal candidate for partnering, particularly in combination with immunotherapies, and specifically in cold tumors."

On November 30, 2022 OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing intratumoral immunotherapies to stimulate the patient’s own immune system to target and eradicate cancer, reported the pricing of its "reasonable best efforts" public offering of 1,166,667 shares of common stock (or common stock equivalents) and Common Warrants to purchase 1,166,667 shares of common stock at a combined price of $3.00 per share, for aggregate gross proceeds of $3.5 million, before deducting placement agent fees and other offering expenses (Press release, OncoSec Medical, NOV 30, 2022, View Source [SID1234624609]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The closing of the offering is expected to occur on or about December 1, 2022, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes, which may include operating expenses, research and development, and future acquisitions.

A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.

The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-268081) previously filed with the Securities and Exchange Commission (SEC) which became effective on November 30, 2022. The offering is being made only by means of a prospectus forming part of the effective registration statement. Copies of the preliminary prospectus and, when available, copies of the final prospectus, relating to the offering may be obtained on the SEC’s website located at View Source Electronic copies of the final prospectus relating to the offering may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

On November 30, 2022 Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, reported that the Company has received formal notice from The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company has regained compliance with the minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)) for continued listing on The Nasdaq Capital Market (Press release, Kintara Therapeutics, NOV 30, 2022, View Source [SID1234624607]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The notice the Company received from Nasdaq on November 29, 2022 noted that the Company evidenced a closing bid price of its shares of common stock at or greater than the $1.00 per share minimum requirement for the last 10 consecutive business days.

On November 30, 2022 Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, reported that senior leadership plans to present at the following conferences (Press release, Iovance Biotherapeutics, NOV 30, 2022, View Source [SID1234624606]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Piper Sandler 34th Annual Healthcare Conference
Fireside Chat: November 30, 2022 at 10:30 a.m. ET / 7:30 a.m. PT
New York, NY

JMP Securities Hematology and Oncology Summit
Fireside Chat: December 7, 2022 at 11:00 a.m. ET / 8:00 a.m. PT
Virtual

41st Annual J.P. Morgan Healthcare Conference
Presentation/Q&A: January 11, 2023 at 11:15 a.m. ET / 8:15 a.m. PT
San Francisco, CA

The live and archived webcasts will be available at View Source